Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_assertion wasGeneratedBy ECO_0000203 NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_assertion wasDerivedFrom befree-20140225 NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_assertion SIO_000772 19424623 NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_assertion evidence source_evidence_literature NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- befree-20140225 importedOn "2014-02-25" NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.